Dr. Marshall's research focuses on the genetics of prostate cancer, as well as clonal hematopoiesis, a risk factor for cardiovascular disease that may be relevant to prostate cancer
This pilot study is determining the feasibility and acceptability for adult and young adult participants patients between the ages of 18 and 39 in ECOG-ACRIN treatment trials to use the National Institutes of Health’s Patient-Reported Outcomes Measurement Information System (PROMIS®)